> R&D > Pipeline > YBL-006
Acrixolimab, anti–PD-1 immuno-oncology agent (YBL-006)
• Completion of global Phase 1/2a trial
• Efficacy and safety confirmed in 67 patients who failed prior cancer therapies
• ORR: 15.9% (2 CR, 8 PR)
Superior efficacy compared to approved anti-PD-1 immunotherapy in NET G3 and NEC
ORR (NET G3 and NEC): 25%
